Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study

por Kampylafka, Eleni, Simon, David, d’Oliveira, Isabelle, Linz, Christina, Lerchen, Veronika, Englbrecht, Matthias, Rech, Juergen, Kleyer, Arnd, Sticherling, Michael, Schett, Georg, Hueber, Axel J.
Publicado 2019

Secukinumab leads to shifts from stage-based towards response-based disease clusters—comparative data from very early and established psoriatic arthritis

por Kampylafka, Eleni, Tascilar, Koray, Lerchen, Veronika, Linz, Christina, Sokolova, Maria, Zekovic, Ana, Kleyer, Arnd, Simon, David, Rech, Jürgen, Sticherling, Michael, Schett, Georg, Hueber, Axel J.
Publicado 2020

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSA...

por Kampylafka, Eleni, d’Oliveira, Isabelle, Linz, Christina, Lerchen, Veronika, Stemmler, Fabian, Simon, David, Englbrecht, Matthias, Sticherling, Michael, Rech, Jürgen, Kleyer, Arnd, Schett, Georg, Hueber, Axel J.
Publicado 2018